Subependymal giant cell astrocytoma pathophysiology

Subependymal giant cell astrocytoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Subependymal giant cell astrocytoma pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Subependymal giant cell astrocytoma pathophysiology
CDC on Subependymal giant cell astrocytoma pathophysiology
Subependymal giant cell astrocytoma pathophysiology in the news
Blogs on Subependymal giant cell astrocytoma pathophysiology
Directions to Hospitals Treating Ependymoma
Risk calculators and risk factors for Subependymal giant cell astrocytoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Pathophysiology

Pathogenesis

• Subependymal giant cell astrocytoma is believed to arise from a subependymal nodule present in the ventricular wall of a patient with tuberous sclerosis.

Genetic

• Development of subependymal giant cell astrocytoma is the result of multiple genetic mutations.
• Genes involved in the pathogenesis of subependymal giant cell astrocytoma include:

• TSC1
• TSC2

• Both the genes, TSC1 and TSC2, are tumor suppressor genes.
• TSC1 is located on chromosome 9q34 and TSC2 is located on chromosome 16p13.
• Protein products of the TSC1 and TSC2 genes, hamartin and tuberin, respectively, form a heterodimer that suppresses the mammalian target of rapamycin (mTOR), a major cell growth and proliferation controller. In tuberous sclerosis complex (TSC), increased mTOR activation leads to disorganized cellular overgrowth, abnormal differentiation, increased protein translation, and the formation of tumors.

Associated Conditions

• Subependymal giant cell astrocytomas are almost exclusively associated with tuberous sclerosis complex, which is an autosomal dominant disorder.
• Subependymal giant cell astrocytomas are characteristic brain tumors that occur in 10% to 20% of tuberous sclerosis patients.

Gross Pathology

• On gross pathology, subependymal giant cell astrocytoma is characterized by:
• Subependymal giant cell astrocytoma typically arises at the caudothalamic groove adjacent to the foramen of Monro.
• Other common intracranial sites associated with subependymal giant cell astrocytoma include:

• Fornix
• Hypothalamus
• Basal ganglia
• Genu of the internal capsule

Gallery

• 
  _{Gross specimen of subependymal giant cell astrocytoma showing a large fleshy mass in the midline and producing marked dilatation of the lateral ventricles.}

Microscopic pathology

On microscopic histopathological analysis, subependymal giant cell astrocytoma is characterized by:

• Giant cells with nuclear atypia ("bizarre cells", "ganglioid cells")
• Vesicular nuclei
• Nuclear pseudoinclusions
• Glassy eosinophilic cytoplasm
• Elongated cells in a fibrillary background
• Abundant mast cells
• Lymphocytic infiltrates
• Endothelial proliferation
• Necrosis

According to the WHO classification of tumors of the central nervous system, subependymal giant cell astrocytoma is classified into a WHO grade I tumor.

Gallery

• 
  _{Typical histology of subependymal giant cell astrocytoma with differentiated giant cells.}

Immunohistochemistry

Subependymal giant cell astrocytoma is demonstrated by positivity to tumor markers such as:

• GFAP +ve (50%)
• Vimentin +ve (100%)
• S-100 +ve (100%)
• Neurofilament +/-ve (ganglionic component)
• Synaptophysin +/-ve (ganglionic component)
• TTF-1
• MIB-1 (1-5%)
• MAP-2 +ve
• Class III beta-tubulin +ve
• Calbindin 28-kD +ve
• Somatostatin +ve
• Met-enkephalin +ve
• 5-hydroxytryptamine +ve
• Beta-endorphin +ve
• Neuropeptide Y +ve

Gallery

• 
  _{Immunohistochemistry staining of a supependymal giant cell astrocytoma showing positivity to GFAP.}

Reference

Template:WikiDoc Sources